Family Comes First as BI Finance Chief Exits Over Future Direction
Executive Summary
The departure of finance chief Simone Menne follows "divergent views" with the board over strategy shows that Boehringer Ingelheim will not countenance any moves that could threaten its independence.
You may also be interested in...
CNS Refresh: Boehringer's New Approach To Tricky Neuropsychiatry Diseases
Boehringer Ingelheim is seeking partners with early-stage, novel approaches to neuropsychiatry disorders under its strategy of applying "fresh thinking" to diseases of the central nervous system with high unmet need.
Deal Watch: Boehringer’s Hectic Stretch Adds Up To Five Deals
Following its partnership with Dicerna, the German pharma signs a second NASH deal with MiNA and inks three cancer-related transactions, including divestitures. Also, Amgen buys out Kirin’s half of their joint venture for $780m.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.